Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Total Valuation
Entrada Therapeutics Inc has a market cap or net worth of $264.09M. The enterprise value is ―.
Market Cap$264.09M
Enterprise Value―
Share Statistics
Entrada Therapeutics Inc has 38,219,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,219,230
Owned by Insiders48.23%
Owned by Institutions0.04%
Financial Efficiency
Entrada Therapeutics Inc’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 9.39%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)9.39%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee1.15M
Profits Per Employee358.61K
Employee Count183
Asset Turnover0.40
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Entrada Therapeutics Inc is ―. Entrada Therapeutics Inc’s PEG ratio is -0.01.
PE Ratio―
PS Ratio3.06
PB Ratio1.50
Price to Fair Value1.50
Price to FCF-14.43
Price to Operating Cash Flow-2.24
PEG Ratio-0.01
Income Statement
In the last 12 months, Entrada Therapeutics Inc had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.
Revenue210.78M
Gross Profit210.78M
Operating Income47.01M
Pretax Income66.48M
Net Income65.63M
EBITDA47.01M
Earnings Per Share (EPS)1.76
Cash Flow
In the last 12 months, operating cash flow was -127.91M and capital expenditures -1.88M, giving a free cash flow of -129.80M billion.
Operating Cash Flow-127.91M
Free Cash Flow-129.80M
Free Cash Flow per Share-3.40
Dividends & Yields
Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.66
52-Week Price Change-65.26%
50-Day Moving Average5.96
200-Day Moving Average7.99
Relative Strength Index (RSI)58.50
Average Volume (3m)202.64K
Important Dates
Entrada Therapeutics Inc upcoming earnings date is Mar 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Entrada Therapeutics Inc as a current ratio of 11.15, with Debt / Equity ratio of 15.38%
Current Ratio11.15
Quick Ratio11.15
Debt to Market Cap0.00
Net Debt to EBITDA-0.89
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Entrada Therapeutics Inc has paid 859.00K in taxes.
Income Tax859.00K
Effective Tax Rate0.01
Enterprise Valuation
Entrada Therapeutics Inc EV to EBITDA ratio is 12.83, with an EV/FCF ratio of -13.49.
EV to Sales2.86
EV to EBITDA12.83
EV to Free Cash Flow-13.49
EV to Operating Cash Flow-14.51
Balance Sheet
Entrada Therapeutics Inc has $326.84M in cash and marketable securities with $52.40M in debt, giving a net cash position of $274.44M billion.
Cash & Marketable Securities$326.84M
Total Debt$52.40M
Net Cash$274.44M
Net Cash Per Share$7.18
Tangible Book Value Per Share$11.49
Margins
Gross margin is 95.76%, with operating margin of 22.30%, and net profit margin of 31.13%.
Gross Margin95.76%
Operating Margin22.30%
Pretax Margin31.54%
Net Profit Margin31.13%
EBITDA Margin22.30%
EBIT Margin22.30%
Analyst Forecast
The average price target for Entrada Therapeutics Inc is $16.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.50
Price Target Upside138.78% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-71.42%
EPS Growth Forecast-248.91%